Exercise for Lung Cancer
(ENHANCE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how different types of exercise affect people with advanced lung cancer who are receiving immune checkpoint inhibitors, a type of cancer therapy. Participants will engage in either high-intensity interval training (short bursts of vigorous exercise) or moderate-intensity continuous training (steady-paced exercise) on a stationary bike. The researchers aim to determine if one type of exercise offers more benefits than the other. This trial targets individuals with advanced non-small cell lung cancer who currently engage in minimal exercise and have a doctor's approval for physical activity. As an unphased trial, it provides a unique opportunity to contribute to understanding how exercise can enhance cancer treatment outcomes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must have been receiving anti-PD-1 or anti-PD-L1 antibodies for at least one month and plan to continue them for at least 12 weeks.
What prior data suggests that these exercise programs are safe for individuals with advanced lung cancer?
Research has shown that High-Intensity Interval Training (HIIT) is safe and well-tolerated for people with cancer. One study found that HIIT helped lung cancer patients experience fewer lung problems after surgery, with a low risk of side effects while improving health. Another review of several studies confirmed that HIIT improved fitness in cancer patients with minimal negative effects.
For Moderate-Intensity Continuous Training (MICT), studies have shown it improves fitness and quality of life in lung cancer patients. Specifically, one study found that exercise programs like MICT were safe and beneficial for overall health. Both HIIT and MICT have shown promise in enhancing physical health with minimal risk, making them good options for those considering joining exercise-based clinical trials.12345Why are researchers excited about this trial?
Researchers are excited about these exercise protocols for lung cancer because they explore how different intensities of exercise can impact patients' health. High-Intensity Interval Training (HIIT) uses short bursts of vigorous exercise followed by recovery periods, which may improve cardiovascular fitness and overall endurance more efficiently than traditional methods. Moderate-Intensity Continuous Training (MICT), on the other hand, provides a steady exercise approach that balances intensity and duration, potentially benefiting those who prefer a less intense but consistent workout. Unlike conventional treatments that focus on medication or surgery, these exercise protocols aim to enhance quality of life and physical performance, offering a complementary approach to existing care.
What evidence suggests that this trial's exercise programs could be effective for lung cancer?
This trial will compare High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) for lung cancer patients. Studies have shown that HIIT can significantly enhance lung function in these individuals. Specifically, research indicates that HIIT increases both VO2peak, which measures the body's oxygen usage, and FEV1, which measures the volume of air exhaled. Additionally, patients who participated in HIIT reported feeling better after 12 weeks. Meanwhile, MICT has effectively reduced cancer-related fatigue and improved overall quality of life for lung cancer patients. Both exercise types show promise in enhancing well-being and fitness levels for these patients.12456
Who Is on the Research Team?
Christina Dieli-Conwright, PhD, MPH
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
The INHALE Trial is for adults over 18 with advanced lung cancer who are on single-agent anti-PD-1 or anti-PD-L1 immunotherapy and can exercise safely. They should do less than 60 minutes of moderate-to-vigorous exercise weekly, not be on other systemic treatments like chemo, and must understand English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 12 weeks of exercise training at different intensities while receiving immune checkpoint inhibitors
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants in the Usual Care group may opt into the exercise program after the initial 12 weeks
What Are the Treatments Tested in This Trial?
Interventions
- High-Intensity Interval Training
- Moderate-Intensity Continuous Training
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
National Cancer Institute (NCI)
Collaborator